While vaccine sales dropped, GSK raised its revenue guidance for 2031 with speciality medicines expected to drive that growth ...

GSK forecast sales in 2025 to grow 3%-5% and reported better-than-expected fourth-quarter earnings, as strength in its HIV ...

London stocks were still a touch higher by midday on Wednesday as investors continued to mull the impact of Trump’s trade war ...

Stock prices in London were mixed on Wednesday afternoon, with a share price rise for GSK supporting the FTSE 100, though tariff worries continue to hang over equities. The FTSE 100 index rose 12.01 ...

By Nikhil Sharma (Reuters) -European shares dipped on Wednesday, as the rise in healthcare companies after Novo Nordisk's ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...

European shares were flat in early trade on Wednesday, as gains led by healthcare stocks following drugmaker Novo Nordisk's ...

In early UK corporate news, GSK announced a buyback and upped its 2031 sales target. Here is what you need to know at the London market open: FTSE 100: called down 0.3% at 8,542.57 Hang Seng: down 1.0 ...

European markets opened mixed on Wednesday, with investors looking ahead to more earnings from a number of key companies.

GSK and the University of Oxford have joined hands to focus on the potential of cancer prevention through vaccination. The ...

The age of targeted cancer therapies brings the potential for more treatment options, greater effectiveness and fewer side effects.

(Alliance News) - Pharmaceutical firm GSK PLC and the University of Oxford are creating a new cancer vaccine to prevent the disease from developing. The partnership intends to create a vaccine or ...